Robert Whitfield MD argues GLP-1 drugs will slash type 2 diabetes rates, which means fewer people needing dialysis. Wall Street has already moved money away from fast food and dialysis companies in anticipation, he says, while pharma focused on short-term sales over the bigger picture.
So I would say if the drug Companies knew what GLP1s were are doing now, they would have never let them be approved. Because think about what they're doing. And you follow the money trail, which you just have to be very plain about this. Wall street has moved money out of fast food and dialysis centers because you're going to see the, the ramifications of these drugs long term is one, a big decrease in diabetes type 2, and two, because of that, a big decrease in dialysis. So those are two huge money. Right. So.
Well, it's like they, they went for the short term win instead of the long term one. Right. You got a lifelong patient with dialysis or you get the money quick now, and it became the number one drug and sold in the world.
